-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
Respiratory -X- _ O
viruses -X- _ O
are -X- _ O
increasingly -X- _ O
recognized -X- _ O
as -X- _ O
significant -X- _ O
etiologies -X- _ O
of -X- _ O
pneumonia -X- _ O
among -X- _ O
hospitalized -X- _ O
patients. -X- _ O
Advanced -X- _ O
technologies -X- _ O
using -X- _ O
multiplex -X- _ O
molecular -X- _ O
assays -X- _ O
and -X- _ O
polymerase-chain -X- _ O
reaction -X- _ O
increase -X- _ O
the -X- _ O
ability -X- _ O
to -X- _ O
identify -X- _ O
viral -X- _ O
pathogens -X- _ O
and -X- _ O
may -X- _ O
ultimately -X- _ O
impact -X- _ O
antibacterial -X- _ O
use -X- _ O
. -X- _ O

METHOD -X- _ O
: -X- _ O
This -X- _ O
was -X- _ O
a -X- _ O
single-center -X- _ O
retrospective -X- _ O
cohort -X- _ O
study -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
antibacterials -X- _ B-Intervention
in -X- _ O
viral -X- _ B-Patient
pneumonia -X- _ I-Patient
on -X- _ O
clinical -X- _ O
outcomes -X- _ O
and -X- _ O
subsequent -X- _ O
multidrug-resistant -X- _ B-Patient
organism -X- _ I-Patient
( -X- _ I-Patient
MDRO -X- _ I-Patient
) -X- _ I-Patient
infections -X- _ I-Patient
/ -X- _ I-Patient
colonization. -X- _ I-Patient
Patients -X- _ O
admitted -X- _ O
from -X- _ O
March -X- _ O
2013 -X- _ O
to -X- _ O
November -X- _ O
2014 -X- _ O
with -X- _ O
positive -X- _ O
respiratory -X- _ O
viral -X- _ O
panels -X- _ O
( -X- _ O
RVP -X- _ O
) -X- _ O
and -X- _ O
radiographic -X- _ O
findings -X- _ O
of -X- _ O
pneumonia -X- _ O
were -X- _ O
included. -X- _ O
Patients -X- _ O
transferred -X- _ O
from -X- _ O
an -X- _ O
outside -X- _ O
hospital -X- _ O
or -X- _ O
not -X- _ O
still -X- _ O
hospitalized -X- _ O
72 -X- _ O
hours -X- _ O
after -X- _ O
the -X- _ O
RVP -X- _ O
report -X- _ O
date -X- _ O
were -X- _ O
excluded. -X- _ O
Patients -X- _ O
were -X- _ O
categorized -X- _ O
based -X- _ O
on -X- _ O
exposure -X- _ O
to -X- _ O
systemic -X- _ B-Intervention
antibacterials -X- _ I-Intervention
: -X- _ O
less -X- _ O
than -X- _ O
3 -X- _ O
days -X- _ O
representing -X- _ O
short-course -X- _ O
therapy -X- _ O
and -X- _ O
3 -X- _ O
to -X- _ O
10 -X- _ O
days -X- _ O
being -X- _ O
long-course -X- _ O
therapy -X- _ O
. -X- _ O

RESULTS -X- _ O
: -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
174 -X- _ B-Patient
patients -X- _ I-Patient
( -X- _ I-Patient
long-course -X- _ I-Patient
, -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
67 -X- _ I-Patient
; -X- _ I-Patient
short-course -X- _ I-Patient
, -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
28 -X- _ I-Patient
; -X- _ I-Patient
mixed -X- _ I-Patient
bacterial-viral -X- _ I-Patient
infection -X- _ I-Patient
, -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
79 -X- _ I-Patient
) -X- _ I-Patient
were -X- _ O
included -X- _ O
with -X- _ O
most -X- _ O
being -X- _ O
immunocompromised -X- _ O
( -X- _ O
56.3 -X- _ O
% -X- _ O
) -X- _ O
with -X- _ O
active -X- _ O
malignancy -X- _ O
the -X- _ O
primary -X- _ O
etiology -X- _ O
( -X- _ O
69.4 -X- _ O
% -X- _ O
) -X- _ O
. -X- _ O
Rhinovirus -X- _ O
/ -X- _ O
Enterovirus -X- _ O
( -X- _ O
23 -X- _ O
% -X- _ O
) -X- _ O
, -X- _ O
Influenza -X- _ O
( -X- _ O
19 -X- _ O
% -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
Parainfluenza -X- _ O
( -X- _ O
15.5 -X- _ O
% -X- _ O
) -X- _ O
were -X- _ O
the -X- _ O
viruses -X- _ O
most -X- _ O
commonly -X- _ O
identified. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
13 -X- _ O
different -X- _ O
systemic -X- _ O
antibacterials -X- _ O
were -X- _ O
used -X- _ O
as -X- _ O
empiric -X- _ O
therapy -X- _ O
in -X- _ O
the -X- _ O
95 -X- _ O
patients -X- _ O
with -X- _ O
pure -X- _ O
viral -X- _ O
infection -X- _ O
for -X- _ O
a -X- _ O
total -X- _ O
of -X- _ O
466 -X- _ O
days-of-therapy. -X- _ O
Vancomycin -X- _ B-Outcome
( -X- _ I-Outcome
50.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
cefepime -X- _ I-Outcome
( -X- _ I-Outcome
40.3 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
azithromycin -X- _ I-Outcome
( -X- _ I-Outcome
40.3 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
meropenem -X- _ I-Outcome
( -X- _ I-Outcome
23.9 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
linezolid -X- _ I-Outcome
( -X- _ I-Outcome
20.9 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
most -X- _ I-Outcome
frequently -X- _ I-Outcome
used. -X- _ I-Outcome
In-hospital -X- _ I-Outcome
mortality -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
differ -X- _ I-Outcome
between -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
viral -X- _ I-Outcome
pneumonia -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
short-course -X- _ I-Outcome
and -X- _ I-Outcome
long-course -X- _ I-Outcome
groups. -X- _ I-Outcome
Subsequent -X- _ I-Outcome
infection -X- _ I-Outcome
/ -X- _ I-Outcome
colonization -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
MDRO -X- _ I-Outcome
was -X- _ I-Outcome
more -X- _ I-Outcome
frequent -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
long-course -X- _ I-Outcome
group -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
short-course -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
53.2 -X- _ I-Outcome
vs -X- _ I-Outcome
21.1 -X- _ I-Outcome
% -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.027 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O

CONCLUSION -X- _ O
: -X- _ O
This -X- _ O
study -X- _ O
found -X- _ O
that -X- _ O
long-course -X- _ B-Outcome
antibacterial -X- _ I-Outcome
use -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
setting -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
pneumonia -X- _ I-Outcome
had -X- _ I-Outcome
no -X- _ I-Outcome
impact -X- _ I-Outcome
on -X- _ I-Outcome
clinical -X- _ I-Outcome
outcomes -X- _ I-Outcome
but -X- _ I-Outcome
increased -X- _ I-Outcome
the -X- _ I-Outcome
incidence -X- _ I-Outcome
of -X- _ I-Outcome
subsequent -X- _ I-Outcome
MDRO -X- _ I-Outcome
infection -X- _ I-Outcome
/ -X- _ I-Outcome
colonization -X- _ I-Outcome
. -X- _ O

